Researchers in the U.K. created a real-time notification system to track children who experienced neurological complications from COVID-19. They found 52 such cases among 1,334 children hospitalized with COVID-19 between April 2, 2020 and Feb. 1, 2021. The estimated prevalence of neurological symptoms in children was 3.8 percent, compared to a previous estimate of 0.9 for hospitalized adults.
Researchers also compared children who developed neurological complications during their initial infection to those who had multisystem inflammatory syndrome in children, or MIS-C, another rare complication of the virus.
“Our nationwide study confirms that children with [MIS-C] can have brain and nerve problems; but we have also identified a wide spectrum of neurological disorders in children due to COVID-19,” lead author Dr. Stephen Ray, a pediatrician at the University of Liverpool, said in a July 16 news release. “These were often due to the child’s immune response after COVID-19 infection.”
During a follow-up period one to six months after discharge, 65 percent of children had good short-term outcomes, researchers found. One-third had some degree of disability due to their neurological complications, and one child died.
Researchers said more follow-up is needed to understand these complications’ long-term effects on children.
To view the full study, click here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
